The effect of adding rituximab to CHOP-based therapy on clinical outcomes for Japanese patients with diffuse large B-cell lymphoma: A propensity score matching analysis

Hisakazu Nishimori, Keitaro Matsuo, Yoshinobu Maeda, Yuichiro Nawa, Kazutaka Sunami, Kazuto Togitani, Hidetaka Takimoto, Yasushi Hiramatsu, Toru Kiguchi, Tomofumi Yano, Hiromichi Yamane, Takayuki Tabayashi, Makoto Takeuchi, Masanori Makita, Nobuo Sezaki, Yoshiko Yamasuji, Haruko Sugiyama, Takahiro Tabuchi, Itaru Kataoka, Nobuharu FujiiFumihiko Ishimaru, Katsuji Shinagawa, Kazuma Ikeda, Masamichi Hara, Tadashi Yoshino, Mitsune Tanimoto

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

We conducted a retrospective analysis to evaluate the impact on clinical outcomes of adding rituximab to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) treatment for diffuse large B-cell lymphoma (DLBCL) patients in Japan. A propensity score method was used to compensate for the non-randomized study design. From January 2000 to December 2004, 378 patients who were newly diagnosed with DLBCL at 13 institutes were enrolled: 123 in the rituximab plus CHOP-based chemotherapy (R+) group, and 255 in the CHOP-based chemotherapy only (R-) group. The complete response rate was significantly higher in the R+ group than in the R- group (77.7 vs. 69.4%, P <0.001). The progression-free survival (PFS) at 2 years was 62.4% in the R+ group and 57.0% in the R- group. The 2-year overall survival (OS) was 76.9% for the R+ group and 70.5% for the R- group. A multivariate analysis revealed that the addition of rituximab was a strong independent prognostic factor for PFS (hazard ratio 0.64, 95% CI 0.43-0.96, P = 0.031). A subgroup analysis revealed that R+ particularly benefited younger patients (hazard ratio 0.25, 95% CI 0.08-0.75, P = 0.013). IPI also showed significant impact for PFS (hazard ratio 1.82, 95% CI 1.55-2.14 for one score increase, P <0.001) as well as OS (hazard ratio 2.10, 95% CI 1.71-2.57, P <0.001). In summary, the addition of rituximab to CHOP-based chemotherapy results in better outcomes for Japanese DLBCL patients, particularly younger patients.

Original languageEnglish
Pages (from-to)326-331
Number of pages6
JournalInternational Journal of Hematology
Volume89
Issue number3
DOIs
Publication statusPublished - Apr 2009

Fingerprint

Propensity Score
Lymphoma, Large B-Cell, Diffuse
Disease-Free Survival
Therapeutics
Drug Therapy
Survival
Vincristine
Prednisone
Doxorubicin
Cyclophosphamide
Japan
Multivariate Analysis
Rituximab

Keywords

  • CHOP
  • DLBCL
  • Non-Hodgkin's lymphoma
  • Rituximab
  • Survival

ASJC Scopus subject areas

  • Hematology

Cite this

The effect of adding rituximab to CHOP-based therapy on clinical outcomes for Japanese patients with diffuse large B-cell lymphoma : A propensity score matching analysis. / Nishimori, Hisakazu; Matsuo, Keitaro; Maeda, Yoshinobu; Nawa, Yuichiro; Sunami, Kazutaka; Togitani, Kazuto; Takimoto, Hidetaka; Hiramatsu, Yasushi; Kiguchi, Toru; Yano, Tomofumi; Yamane, Hiromichi; Tabayashi, Takayuki; Takeuchi, Makoto; Makita, Masanori; Sezaki, Nobuo; Yamasuji, Yoshiko; Sugiyama, Haruko; Tabuchi, Takahiro; Kataoka, Itaru; Fujii, Nobuharu; Ishimaru, Fumihiko; Shinagawa, Katsuji; Ikeda, Kazuma; Hara, Masamichi; Yoshino, Tadashi; Tanimoto, Mitsune.

In: International Journal of Hematology, Vol. 89, No. 3, 04.2009, p. 326-331.

Research output: Contribution to journalArticle

Nishimori, H, Matsuo, K, Maeda, Y, Nawa, Y, Sunami, K, Togitani, K, Takimoto, H, Hiramatsu, Y, Kiguchi, T, Yano, T, Yamane, H, Tabayashi, T, Takeuchi, M, Makita, M, Sezaki, N, Yamasuji, Y, Sugiyama, H, Tabuchi, T, Kataoka, I, Fujii, N, Ishimaru, F, Shinagawa, K, Ikeda, K, Hara, M, Yoshino, T & Tanimoto, M 2009, 'The effect of adding rituximab to CHOP-based therapy on clinical outcomes for Japanese patients with diffuse large B-cell lymphoma: A propensity score matching analysis', International Journal of Hematology, vol. 89, no. 3, pp. 326-331. https://doi.org/10.1007/s12185-009-0259-8
Nishimori, Hisakazu ; Matsuo, Keitaro ; Maeda, Yoshinobu ; Nawa, Yuichiro ; Sunami, Kazutaka ; Togitani, Kazuto ; Takimoto, Hidetaka ; Hiramatsu, Yasushi ; Kiguchi, Toru ; Yano, Tomofumi ; Yamane, Hiromichi ; Tabayashi, Takayuki ; Takeuchi, Makoto ; Makita, Masanori ; Sezaki, Nobuo ; Yamasuji, Yoshiko ; Sugiyama, Haruko ; Tabuchi, Takahiro ; Kataoka, Itaru ; Fujii, Nobuharu ; Ishimaru, Fumihiko ; Shinagawa, Katsuji ; Ikeda, Kazuma ; Hara, Masamichi ; Yoshino, Tadashi ; Tanimoto, Mitsune. / The effect of adding rituximab to CHOP-based therapy on clinical outcomes for Japanese patients with diffuse large B-cell lymphoma : A propensity score matching analysis. In: International Journal of Hematology. 2009 ; Vol. 89, No. 3. pp. 326-331.
@article{6e94944f6b784592a8088a3409b7c4e4,
title = "The effect of adding rituximab to CHOP-based therapy on clinical outcomes for Japanese patients with diffuse large B-cell lymphoma: A propensity score matching analysis",
abstract = "We conducted a retrospective analysis to evaluate the impact on clinical outcomes of adding rituximab to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) treatment for diffuse large B-cell lymphoma (DLBCL) patients in Japan. A propensity score method was used to compensate for the non-randomized study design. From January 2000 to December 2004, 378 patients who were newly diagnosed with DLBCL at 13 institutes were enrolled: 123 in the rituximab plus CHOP-based chemotherapy (R+) group, and 255 in the CHOP-based chemotherapy only (R-) group. The complete response rate was significantly higher in the R+ group than in the R- group (77.7 vs. 69.4{\%}, P <0.001). The progression-free survival (PFS) at 2 years was 62.4{\%} in the R+ group and 57.0{\%} in the R- group. The 2-year overall survival (OS) was 76.9{\%} for the R+ group and 70.5{\%} for the R- group. A multivariate analysis revealed that the addition of rituximab was a strong independent prognostic factor for PFS (hazard ratio 0.64, 95{\%} CI 0.43-0.96, P = 0.031). A subgroup analysis revealed that R+ particularly benefited younger patients (hazard ratio 0.25, 95{\%} CI 0.08-0.75, P = 0.013). IPI also showed significant impact for PFS (hazard ratio 1.82, 95{\%} CI 1.55-2.14 for one score increase, P <0.001) as well as OS (hazard ratio 2.10, 95{\%} CI 1.71-2.57, P <0.001). In summary, the addition of rituximab to CHOP-based chemotherapy results in better outcomes for Japanese DLBCL patients, particularly younger patients.",
keywords = "CHOP, DLBCL, Non-Hodgkin's lymphoma, Rituximab, Survival",
author = "Hisakazu Nishimori and Keitaro Matsuo and Yoshinobu Maeda and Yuichiro Nawa and Kazutaka Sunami and Kazuto Togitani and Hidetaka Takimoto and Yasushi Hiramatsu and Toru Kiguchi and Tomofumi Yano and Hiromichi Yamane and Takayuki Tabayashi and Makoto Takeuchi and Masanori Makita and Nobuo Sezaki and Yoshiko Yamasuji and Haruko Sugiyama and Takahiro Tabuchi and Itaru Kataoka and Nobuharu Fujii and Fumihiko Ishimaru and Katsuji Shinagawa and Kazuma Ikeda and Masamichi Hara and Tadashi Yoshino and Mitsune Tanimoto",
year = "2009",
month = "4",
doi = "10.1007/s12185-009-0259-8",
language = "English",
volume = "89",
pages = "326--331",
journal = "International Journal of Hematology",
issn = "0925-5710",
publisher = "Springer Japan",
number = "3",

}

TY - JOUR

T1 - The effect of adding rituximab to CHOP-based therapy on clinical outcomes for Japanese patients with diffuse large B-cell lymphoma

T2 - A propensity score matching analysis

AU - Nishimori, Hisakazu

AU - Matsuo, Keitaro

AU - Maeda, Yoshinobu

AU - Nawa, Yuichiro

AU - Sunami, Kazutaka

AU - Togitani, Kazuto

AU - Takimoto, Hidetaka

AU - Hiramatsu, Yasushi

AU - Kiguchi, Toru

AU - Yano, Tomofumi

AU - Yamane, Hiromichi

AU - Tabayashi, Takayuki

AU - Takeuchi, Makoto

AU - Makita, Masanori

AU - Sezaki, Nobuo

AU - Yamasuji, Yoshiko

AU - Sugiyama, Haruko

AU - Tabuchi, Takahiro

AU - Kataoka, Itaru

AU - Fujii, Nobuharu

AU - Ishimaru, Fumihiko

AU - Shinagawa, Katsuji

AU - Ikeda, Kazuma

AU - Hara, Masamichi

AU - Yoshino, Tadashi

AU - Tanimoto, Mitsune

PY - 2009/4

Y1 - 2009/4

N2 - We conducted a retrospective analysis to evaluate the impact on clinical outcomes of adding rituximab to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) treatment for diffuse large B-cell lymphoma (DLBCL) patients in Japan. A propensity score method was used to compensate for the non-randomized study design. From January 2000 to December 2004, 378 patients who were newly diagnosed with DLBCL at 13 institutes were enrolled: 123 in the rituximab plus CHOP-based chemotherapy (R+) group, and 255 in the CHOP-based chemotherapy only (R-) group. The complete response rate was significantly higher in the R+ group than in the R- group (77.7 vs. 69.4%, P <0.001). The progression-free survival (PFS) at 2 years was 62.4% in the R+ group and 57.0% in the R- group. The 2-year overall survival (OS) was 76.9% for the R+ group and 70.5% for the R- group. A multivariate analysis revealed that the addition of rituximab was a strong independent prognostic factor for PFS (hazard ratio 0.64, 95% CI 0.43-0.96, P = 0.031). A subgroup analysis revealed that R+ particularly benefited younger patients (hazard ratio 0.25, 95% CI 0.08-0.75, P = 0.013). IPI also showed significant impact for PFS (hazard ratio 1.82, 95% CI 1.55-2.14 for one score increase, P <0.001) as well as OS (hazard ratio 2.10, 95% CI 1.71-2.57, P <0.001). In summary, the addition of rituximab to CHOP-based chemotherapy results in better outcomes for Japanese DLBCL patients, particularly younger patients.

AB - We conducted a retrospective analysis to evaluate the impact on clinical outcomes of adding rituximab to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) treatment for diffuse large B-cell lymphoma (DLBCL) patients in Japan. A propensity score method was used to compensate for the non-randomized study design. From January 2000 to December 2004, 378 patients who were newly diagnosed with DLBCL at 13 institutes were enrolled: 123 in the rituximab plus CHOP-based chemotherapy (R+) group, and 255 in the CHOP-based chemotherapy only (R-) group. The complete response rate was significantly higher in the R+ group than in the R- group (77.7 vs. 69.4%, P <0.001). The progression-free survival (PFS) at 2 years was 62.4% in the R+ group and 57.0% in the R- group. The 2-year overall survival (OS) was 76.9% for the R+ group and 70.5% for the R- group. A multivariate analysis revealed that the addition of rituximab was a strong independent prognostic factor for PFS (hazard ratio 0.64, 95% CI 0.43-0.96, P = 0.031). A subgroup analysis revealed that R+ particularly benefited younger patients (hazard ratio 0.25, 95% CI 0.08-0.75, P = 0.013). IPI also showed significant impact for PFS (hazard ratio 1.82, 95% CI 1.55-2.14 for one score increase, P <0.001) as well as OS (hazard ratio 2.10, 95% CI 1.71-2.57, P <0.001). In summary, the addition of rituximab to CHOP-based chemotherapy results in better outcomes for Japanese DLBCL patients, particularly younger patients.

KW - CHOP

KW - DLBCL

KW - Non-Hodgkin's lymphoma

KW - Rituximab

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=67649159580&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67649159580&partnerID=8YFLogxK

U2 - 10.1007/s12185-009-0259-8

DO - 10.1007/s12185-009-0259-8

M3 - Article

C2 - 19326060

AN - SCOPUS:67649159580

VL - 89

SP - 326

EP - 331

JO - International Journal of Hematology

JF - International Journal of Hematology

SN - 0925-5710

IS - 3

ER -